Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$121.12 USD
-1.68 (-1.37%)
Updated May 17, 2024 04:00 PM ET
After-Market: $121.15 +0.03 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ASND 121.12 -1.68(-1.37%)
Will ASND be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASND
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
Other News for ASND
$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
Ascendis Pharma price target raised by $24 at Morgan Stanley, here's why
Ascendis Pharma Expands Capital with Warrants and Shares
Analyst Issues ‘Buy’ Rating on Ascendis Pharma, Anticipates FDA Approval for TransCon PTH
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months